drugset / Trial / NCT05877924
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.
Timeline
- Start
- 2023-08-15
- Primary completion
- 2025-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBL-020 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | NBL-020 | Unknown | 30 mg/kg | Intravenous |